Exosome Therapy for Stroke

Jieli Chen, MD; Michael Chopp, PhD

Nearly, all cells generate and eject vesicles, and these vesicles constitute major vehicles for intercellular communication. Exosomes, as nanosized vesicles (≈30–100 nm in diameter[1]), target cell function by delivering proteins, lipids, and nucleic acids. Exosomes are emerging as a valuable source for disease stage–specific information and as fingerprints of disease progression and as potential biomarkers in different pathophysiological states.[2–5] However, because exosomes provide a major medium of intercellular communication,[6] they likely also impact the treatment of diseases.[7,8] Recent reports have highlighted the critical application of exosomes as personalized targeted drug delivery vehicles.[6,9] Exosomes harvested from multipotent mesenchymal stromal cells (MSCs) mediate the restorative therapeutic effects of MSCs for stroke.[10] Here, we review the biogenesis of exosomes and their molecular composition and role as messengers of intercellular communication and describe using exosomes for treatment of stroke. We also focus on therapeutic effects and underlying mechanisms of action of exosomes as therapeutic vectors for stroke[11] but do not discuss the role of exosomes as disease or injury biomarkers. Capitalizing on the function of exosomes as vehicles for intercellular communication in physiological and pathophysiological conditions such as stroke provides a paradigm shift and enormous potential for safe and effective therapeutic approaches for stroke and for other diseases/injury.

Exosome Biogenesis and Content

Exosomes are highly conserved among most eukaryotic organisms, from microorganisms up to mammals.[12] Exosomes originate from the endocytic route and are formed by the inward budding of the plasma membrane. The membrane of late endosomes invaginates and forms small vesicles that are pinched off into the endosomal space. The internal intraluminal vesicles with their cargo secreted into the extracellular space are exosomes.[13]

Exosomes contain conserved proteins, such as CD81, CD63 (membrane-associated proteins like LAMP-3 [lysosome-associated membrane protein 3]), and CD9; Alix and tumor susceptibility gene 101 protein[9]; and tissue/cell type-specific proteins that reflect their cellular source.[14] The exosome membranes are enriched with cholesterol, sphingomyelin, and ceramide.[15] Exosomes contain many biologically active molecules, such as proteins, RNAs, DNAs, lipids, and microRNAs (miRs).[16] These bioactive molecules mediate exosomal intercellular communication and may target specific cell types and thereby modify their target cell function by delivering proteins, lipids, and nucleic acids.[17] Most proteins within exosomes are derived from parent cell membranes, the cytosol, and Golgi but rarely from endoplasmic reticulum or mitochondria.[12] Cytosolic proteins remain within the exosomes, and those derived from the plasma membrane are retained in the vesicle membrane, maintaining the same topology of the cell, with potential roles in sequestering soluble ligands.[18] Exosome proteins participate in antigen presentation, cell adhesion, and cell structure and motility and are stress regulators, involved in transcription and protein synthesis and in trafficking and membrane fusion.[19] Many functional effects of exosomes may be attributed to the transfer of their RNA and miR content.[17] RNAs and miRs are the most relevant cargo in exosomes in terms of the ability of a small number of molecules to influence several proteins/enzymes within one or more cellular pathways in target cells.[20]

Exosome Isolation and Storage

Many methods for exosome isolation have been described.[21,22] They include (1) differential centrifugation coupled with ultracentrifugation[15,23]; (2) using anti-EpCAM (epithelial cell adhesion molecule)–coated magnetic beads immunoaffinity pull-down[24,25]; (3) density gradient separation[25]; (4) sequential centrifugal ultrafiltration by tangential flow filtration[26]; (5) using ExoQuick-TC[27]; (6) rapid isolation of exosome by alternating current electrokinetic microarray chip device[28]; and (7) using a commercially available size exclusion chromatography column for rapid vesicle purification.[29] Ultracentrifugation-isolated exosomes have the highest protein purity, but the lowest recovery of particles.[30] Specific g-force/k factor usage during differential ultracentrifugation also influences the purity and yield of exosomes.[31] Baranyai et al[32] compared the purity of exosomes using differential ultracentrifugation and

Received July 14, 2017; final revision received August 28, 2017; accepted August 30, 2017.

From the Department of Neurology, Henry Ford Hospital, Detroit, MI (J.C., M.C.); Department of Geriatrics, Tianjin Medical University General Hospital, China (J.C.); Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma Neurorepair and Regeneration in Central Nervous System, Ministry of Education, China (J.C.); and Department of Physics, Oakland University, Rochester, MI (M.C.).

Correspondence to Michael Chopp, PhD, Department of Neurology, E&R Bldg, Room no. 3067, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202, E-mail mchopp1@hfhs.org or Jieli Chen, MD, Department of Neurology, E&R Bldg, Room no. 3091, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202, E-mail jieli@neuro.hfh.edu

(*Stroke*. 2018;49:1083-1090. DOI: 10.1161/STROKEAHA.117.018292.)

size exclusion chromatography. They found that using ultracentrifugation isolation, the diameter of the majority of isolated particles fell into the size range of exosomes; however, albumin was also present in the preparations, when 1 hour of ultracentrifugation at 4°C was applied.[32] Size exclusion chromatography isolation showed good reproducibility and rapid vesicle purification (<10 minutes); however, postcolumn exosome concentration steps resulted in some protein loss and also leads to low exosome recovery and reduced purity (assessed by the particle-to-protein ratio).[29] Van Deun et al,[33]compared 4 methods of exosome extraction: differential ultracentrifugation, OptiPrep density gradient centrifugation, ExoQuick precipitation, and Total Exosome Isolation precipitation. They found that ultracentrifugation and OptiPrep density gradient centrifugation showed better clean exosome preparations measured by CD63-immuno-TEM than ExoQuick and Total Exosome Isolation precipitation. OptiPrep density gradient centrifugation showed the purest exosome preparations.[33] However, Taylor et al[34] indicated that circulating exosomes isolated by ExoQuick precipitation produces exosomal RNA and protein with greater purity and quantity than chromatography, ultracentrifugation, and DynaBeads. Therefore, to date, there is no gold-standard method for exosome isolation, which complicates interlaboratory comparisons of data.[21]

Exosome storage conditions (such as temperature and duration) influence the therapeutic utility of exosomes and their stability. Protein and RNA content of exosomes decrease at 10 days of room temperature storage compared with storage at −70 and 4°C.[35] Exosomes are stable at 4°C for short term (within 7 days) and when stored at −80°C for at least 90 days.[25] Storage at below −70°C is the most favorable condition for long-term preservation of fresh exosomes for clinical application and basic research.[35]

Interaction of Exosomes With Target Cells

Exosomes are taken up by target cells by several mechanisms, most of which are mediated by the endocytosis route, such as clathrin-mediated endocytosis,[36] phagocytosis,[37] lipid raft-mediated internalization,[38] and macropinocytosis,[39] and by direct fusion with the plasma membrane.[40] Exosomes bind to target cells via ligand–receptor interactions, such as integrins, tetraspanins, and intercellular adhesion molecules. Tetraspanins as a functionally important component of exosomes also have specific effects on distinct cell fission and fusion machineries.[41] After binding, exosomal contents are internalized by recipient cells via fusion with the plasma membrane of recipient cells and direct release of contents into the cytoplasm or by exosome internalization by endocytosis into recipient cells. The exosomal tetraspanin web regulates target cell selection and facilitates tailoring exosomes for drug delivery.[42] Human brain endothelial cell–derived exosomes contain several receptors to carry macromolecules across the blood–brain barrier, including transferrin receptor, insulin receptor, low-density lipoprotein, low-density lipoprotein receptor–related protein, and TMEM30A (a putative antigen for the single-domain antibody), and human brain endothelial cell-derived exosomes act as cell communication vesicles with both brain astrocytes and cortical neurons.[43] Therefore, exosomes are promising tools to target drugs or biological material to specific cells across different biological barriers, and exosomes mediate cell-to-cell interaction.[6,8]

Exosome Effects on Immunoresponse

Exosomes communicate with cells, participate in the cascade of antigen presentation, and are implicated in various essential immunologic processes such as immune surveillance.[44] Exosomes derived from dendritic cells are antigen-presenting and have been used for treatment of brain tumor in phase I and II clinical trials.[45,46] Exosomes can cross the blood–brain barrier and transfer brain antigens to the periphery and regulate the peripheral immune system.[47,48] Exosomes secreted by resident brain cells in response to pathogenic stimuli also influence bystander cells by the transfer of dysregulated miRs that suppress the expression of essential genes in the recipient cells.[49] Stroke and central nervous system neuroinflammatory diseases, such as multiple sclerosis, regulate peripheral immune response via exosomes.[47,50] Microglial exosomes and astrocyte exosomes store and release the inflammatory cytokine IL-1β (interleukin-1β).[51,52]

Exosomes also transfer proinflammatory messages from the periphery to recipient brain cells. Balusu et al[53] found that the choroid plexus epithelium cells sense and transmit peripheral inflammatory signals to the brain via the release of exosomes. These choroid plexus epithelium exosomes enter brain parenchyma and are taken up by astrocytes and microglia, inducing miR target repression and inflammatory gene upregulation.[53] Microglia-derived extracellular vesicles can stimulate neuronal activity and participate in the propagation of inflammatory signals.[54] Exosomes isolated from circulating immune cells from conditions of environmental enrichment increase oligodendrocyte progenitor cell differentiation into myelinating cells in cultured hippocampal slices and promote myelination in vivo when intranasally administered to naive rats.[55] Thus, exosomes as mediators of neuroinflammation may impact stroke outcome.[49]

Exosome Effects on Thrombosis

Circulating exosomes participate in the coagulation cascade by providing a surface for the assembly of clotting factors.[56] In intracerebral hemorrhage, cerebrospinal fluid and plasma procoagulant microvesicle/exosomes levels are significantly increased and may contribute to stroke pathogenesis.[57] Platelet microvesicles/exosomes have 50- to 100-fold higher specific procoagulant activity than activated platelets.[58] Circulating microvesicles/exosomes derived from endothelial cells and blood cells may promote procoagulant activity and thrombin generation.[59] However, compared with microvesicles and apoptotic vesicles, exosomes have reduced coagulation and immunogenic effects.[60] Manipulating thrombosis and the coagulation cascade via exosomes as an intervention for ischemic stroke warrants investigation.

Therapeutic Effects of Exosomes on Stroke

Exosomes transport cell type–specific molecular cargo extracellularly and over large distances. In addition, the same exosomes may evoke differential response in different cells.

Neural released exosomes not only regulate the onset and progression of neurodegenerative and neuroinflammatory diseases but also may play a role in the regeneration and remodeling of the nervous system after stroke.[61] Neural secreted exosomes contribute to local synaptic plasticity and also influence neuronal networks by long-range communication within the central nervous system. Therefore, by inhibiting their release from diseased cells and by manipulating their cargo to enable shuttling of secretory RNA, miR, or molecules such as cytokines, chemokines, and growth factors,[62] exosomes may function as therapeutic agents.[56]

Advantages of Using Stem Cell–Derived Exosomes for Stroke Therapy

Cell-based therapies for stroke improve neurological outcome.[63–66] The mechanisms of cell-based therapy–induced therapeutic effects after stroke are not mediated via cell replacement or transplanted cell differentiation into brain cells.[14,66] Secreted paracrine factors from stem cells are the principal mechanism underlying their therapeutic action in stroke.[14] Using stem cell–secreted paracrine factors and cell-free therapy are likely safer alternatives in promoting brain plasticity after stroke and in neurodegenerative disease. Recently, a variety of cell types have been shown to secrete paracrine factors that are contained within membrane vesicles, such as exosomes, microvesicles, ectosomes, membrane particles, and apoptotic bodies.[18] Extracellular vesicles have emerged as important mediators of intercellular communication, being involved in the transmission of biological signals between cells.[56] Treatment of stroke and neural injury with extracellular vesicles, that is, exosomes, harvested from MSCs, rather than the exosome parent MSCs, supplants the therapeutic benefits of administration of the parent MSCs.[8,10] Exosomes are specifically internalized by recipient cells, which avoids a multiplicity of potential concerns associated with administration of living cells, and exosomes provide therapeutic benefit, at least the equivalent of their cellular source. Compared with cell therapy, the advantages of exosome-based therapy include[9,14] (1) low immunogenicity[56]; (2) no vascular obstructive effect and reduced risk of secondary microvascular thrombosis[14]; (3) systemically injected exosomes are able to cross the blood–brain barrier and enter the brain parenchyma[67,68]; (4) the potential to develop large-scale cellular factories of engineered therapeutic vesicles[17]; (5) exosomes have higher surface/volume ratio and amplify ligand-gated signaling pathways and the transfer of biomolecules from stem cells to target tissues; and (6) ability to readily modify exosome miR content. Here, we review the possible application of exosomes for the treatment of stroke, to provide a safe and effective alternative to cell-based therapy.[7,69] In the following section, we discuss exosome therapy for stroke, which is summarized in Figure.

MSC-Exosome for Treatment of Stroke

Compared with other cell types, the MSC is a prolific exosome producer.[70] Using proteomic analysis, Otero-Ortega et al[67] identified >2000 proteins in MSC-exosome (MSC-Exo), many of which may be implicated in brain repair. MSCs induce neurological recovery poststroke and neural injury, primarily by paracrine effects via MSC-secreted exosomes, which mediate restorative actions of MSCs.[10,71–73] MSC-Exos taken up by endothelial cells, dose dependently increase endothelial cell proliferation, migration, and capillary tube formation, as well as impair T-cell function by inhibiting T-cell proliferation in vitro.[74] Systemically injecting bone marrow–derived MSC-Exo at 1 day after ischemic stroke or traumatic brain injury significantly improves functional outcome, as well as enhances angiogenesis, neurogenesis, and neurite remodeling in rats.[10,75–78] Similarly, human MSC-Exo treatment of stroke increases long-term neuroprotection, promotes neuroregeneration, enhances neurological recovery, and modulates peripheral poststroke immune responses but does not affect cerebral immune cell infiltration in mice.[79] MSC-Exos significantly improve functional outcome and reduce structural injury and show promise in treating global hypoxic–ischemic injury of the fetal brain.[80] Human MSC-Exo treatment dose dependently reduces brain neuroinflammation after traumatic brain injury in mice[81] and significantly ameliorates inflammation-induced neuronal cellular degeneration, reduces microgliosis, prevents reactive astrogliosis, and improves functional recovery in traumatic brain injury animals.[82,83] Adipose-derived MSC-Exo treatment initiated at 3 hours after ischemic stroke was safe, decreasing lesion volume, increasing angiogenesis, demonstrating anti-inflammatory and immunomodulatory capacity, and improving neurological function in rats.[84] Intravenous administration of MSC-Exos to rats subjected to intracerebral hemorrhage significantly promotes white matter/axonal remodeling identified by fiber tract integrity, white matter repair, and axonal sprouting and decreases neurological functional deficits compared with the control group at 28 days after intracerebral hemorrhage.[67]

Multicellular Sources of Microparticles or Exosomes as a Treatment of Stroke

In addition to MSC-Exo, exosomes derived from other cell types also induce neuroprotective and neurorestorative effects after stroke. Exosomes derived from human adipose-derived stem cells increase expression of protein kinase CδII in immortalized mouse hippocampal cell line and increase neuronal survival and proliferation.[85] Platelet-derived microparticles dose dependently increase endogenous neural stem cell proliferation, neurogenesis, and angiogenesis in the ischemic brain and significantly improve neurological functional outcome after ischemic stroke in rats.[86] Microparticles derived from activated platelets contain a variety of growth factors augmenting endogenous neural progenitor cell proliferation and neurovascular remodeling, which may be utilized for stroke therapy.[86,87] Altmann et al[88] showed that secretomes derived from rat and human apoptotic mononuclear cells also induce neuroprotective effects identified by decreased lesion volume and improved functional neurological outcome. Therefore, exosomes and microvesicles derived from a variety of cells induce angiogenesis, suppress apoptosis, stimulate cell proliferation, promote neurogenesis and synaptic plasticity, deliver immunomodulatory signals, and recruit and reprogram cells and restorative events that in concert improve functional recovery after stroke.



Figure. Summary of the therapeutic effects of exosome in stroke: (1) Intravenous administration of exosomes can pass the blood–brain barrier (BBB) and are taken up by endogenous brain cells. (2) Exosomes contain microRNAs (miRs), mRNA, and proteins (such as CD81, CD63, CD9, Alix, etc, as well as cell type–specific antigens); (3) Exosomes interact with target cells and transfer their RNA, miR, and protein content by: (i), the endocytosis route (pinocytosis and phagocytosis); (ii) direct fusion with the plasma membrane; and (iii) binding to target cell via ligand–receptor interactions (such as integrins, tetraspanins, and intercellular adhesion molecules). (4) Exosomes communicate with endogenous brain cells and induce neurogenesis and white matter/axonal and vascular remodeling, as well as inhibit neuroinflammation, and thereby promote neuroprotective or neurorestorative effects, as well as improve functional outcome after stroke. MSV indicates multivesicular body.

Exosome Treatment Effects by Transfer of miR

Exosomes contain miRs that play important roles in cell function, disease, and immunomodulation.[7,8,89] Systemic administration of MSC-Exos improve neurological functional outcome in animal models of stroke, impacting post-transcriptional gene expression and ensuing protein expression in their target cells via transfer of miRs.[76] miRs are short sequences of noncoding RNA that function in RNA silencing and post-transcriptional regulation of gene expression.[90] Among their myriad of functional properties, miRs also regulate neurovascular remodeling, inflammation, and stem cell biology.[91] We also note that MSC-harvested exosomes also stimulate endogenous brain cells to subsequently release miRs, in a chain reaction–like manner, ultimately promoting brain plasticity after stroke.[92] In addition, MSCs inhibit macrophage activation by shedding miR-containing exosomes.[89] In vitro data show that exosomes derived from environmental enrichment serum promote oligodendrocyte precursor cell differentiation into myelinating cells and reduce oxidative stress.[55] MSC-Exos promote axonal growth, and inhibition of argonaut 2 protein (a primary miR machinery protein) abolishes MSC-Exos–induced axonal growth.[75] MSCs communicate with brain parenchymal cells and regulate neurite outgrowth by transfer of miRs, such as miR-133b, to neural cells via exosomes.[76] Collectively, these data demonstrate that exosomes mediate their functional benefit in stroke at least partially by the transfer of miRs to parenchymal cells.

Modification of Exosomes

Exosomes have low toxicity, high stability in the circulation, and high efficiency of transport to donor cells. Modified exosomes have been used as vehicles to transport exogenous chemical compounds to recipient cells. Exosomes are valuable for the delivery of RNA interference and miR regulatory molecules, in addition to other single-stranded oligonucleotides.[93] Intravenous administration of neuronal-targeted exosomes loaded with specific siRNA knocked down their target genes in neurons.[94] Curcumin, an anti-inflammatory agent, can be encapsulated in exosomes.[95] Intranasal administration of curcumin-encapsulated exosomes in ischemic stroke mice significantly reduced astrogliosis and increased the expression of NeuN (feminizing locus on X-3, Fox-3, Rbfox3, or hexaribonucleotide binding protein-3) and vascular endothelial tight junction proteins when compared with nontreated stroke mice.[95]

Exosomes also contain distinct subsets of miRs depending on the cell type source.[96] Modulation of miRs within stem cells and thereby within exosomes derived from the parent cell may enhance exosome-induced therapeutic efficacy. MSC-Exo can be enriched with specific miRs to enhance recovery of injured tissues.[8,14] MSCs release functional small RNAs via their exosomes.[10,71–73] In vitro, the miR-17 to 92 cluster promotes oligodendrogenesis, neurogenesis, and axonal outgrowth.[97] Treatment of stroke in rat with MSC-Exo and miR-17 to 92 enriched MSC-Exo both significantly improved neurological functional recovery, but miR-17 to 92 cluster enriched exosome treatment induced significantly more improvement of functional outcome and enhancement of neurogenesis, oligodendrogenesis, and neuronal dendrite plasticity in the ischemic brain than the control MSC-Exo treatment.[97] Tailored exosomes derived from MSCs further enhance neurite growth via the phosphatase and tensin homologue/mammalian target of rapamycin signals by increasing the miR-17 to 92 cluster.[98] Exosomes derived from miR-133b–overexpressed MSCs and miR-17 to 92 cluster enriched exosomes significantly increase brain plasticity and neurological functional recovery after stroke compared with MSC-Exo–treated stroke rats.[97,99] In vitro data also show that exosomes harvested from astrocytes subjected to oxygen glucose deprivation treated with miR-133b–overexpressing MSC-Exo significantly increased neurite outgrowth in cultured primary cortical neurons compared with the exosomes derived from oxygen glucose deprivation astrocytes subjected to MSC-Exo-control.[99]

Thus, in vivo and in vitro data suggest that modulating miR content of exosome may be an effective means to amplify the therapeutic effects of exosomes for the treatment of stroke and neurological injury, as well as degenerative diseases.[8]

Caveats and Future Studies

Although exosomes exhibit promising therapeutic effects, exosome-based therapy for stroke has just recently emerged, and many additional studies are warranted to move this therapy to the clinic. Among the considerations and studies to be performed are the following: (1) scaling production of exosomes for human clinical trials will be required. Recent publications suggest that these production and scaling methods are actively being pursued.[21,22] In addition, cell culture conditions and storage methods may have a major impact on the exosome content and their functionality. Appropriate exosome isolation methods, storage, and functional read-out systems need to be standardized. (2) Exosome content, function, and activity depend on the generating cells of origin. Therefore, exosome cell source, including age, sex, comorbidities, and other factors associated with the exosome-generating cells should be optimized. (3) Although initial preclinical studies have shown that a single dose of exosomes administered poststroke is highly efficacious in promoting neurological recovery, we cannot exclude the possibility that multiple dosing, particularly for different types of strokes, may further improve neurological outcomes. (4) Dose–response and therapeutic window studies are required. Given the reported extended therapeutic window for treatment of stroke with cell-based therapies, exosomes may likewise provide an extended therapeutic window. Previous studies have shown that exosome treatment initiated at 24 hours after brain hemorrhage or ischemic stroke significantly improves functional outcome, decreases lesion volume, and promotes axonal/white matter remodeling for both hemorrhage and stroke.[10,67,76,79,97,99] Adipose-derived mesenchymal stem cell-derived exosome treatment of stroke initiated at 50 minutes or 3 hours after stroke reduced lesion volume and enhanced neurological recovery in rat.[84] Thus, exosome treatment of stroke not only induces neurorestoration but also promotes neuroprotection. However, some therapeutic interventions provide therapeutic benefit in the acute phase of stroke but impair regeneration in the chronic phase and vice versa.[100] Therefore, investigation of the optimal timing of exosome therapy, which may be affected by the parental cell source, is required. (5) Of primary importance is the performance of safety studies for stroke using exosomes. These studies should include safety in patients with comorbidities. Particularly, studies should be performed to ensure that the restorative exosomes are not oncogenic and further promote tumor growth. Enhancing tissue regeneration after stroke in the central nervous system may increase the risk to activate cancer.[100] Induction of neurovascular remodeling is itself associated with angiogenic and cell proliferative events.[101] In addition, exosomes contain many miRs, such as miR-9, miR-223, and miR-126, which not only induce neural repair or axonal growth responses but also closely linked with oncogenesis.[102–105] Potential oncogenic features of extracellular vesicles or exosomes are being addressed in the literature.[106] Further studies, however, are warranted to evaluate the oncogenic potential of restorative therapy for stroke. Therefore, safety, time window, dose–response, multiple dosing, and oncogenic potential studies, among others, are required for effective and safe translation of this promising restorative and neuroprotective therapeutic approach for the treatment of stroke.

Conclusions

Exosomes have multifaceted roles in the regulation of physiological and pathological processes and importantly may also function as therapeutic agents. Exosomes derived from different cells can induce neuroprotection and neurorestorative effects by modulating gene, protein, and miR expression in their target cells and tissues. Exosomes from specific cells, such as MSCs, and likely other cells, reduce inflammation and increase angiogenesis, neurogenesis, and white matter remodeling after stroke. Modified exosomes can be used as vehicles to transport exogenous genes, proteins, and chemical compounds to recipient cells. Modulation of genes and miRs in exosome parent cells enhances exosome-induced therapeutic efficacy.[72,76,97] Therefore, exosomes may potentially be used as personalized targeted drug delivery vehicles.[6,9] However, we should cautiously and carefully develop this promising therapy. Safety, time window, and dose–response studies are just a part of the range of investigations that will be performed before the translation of exosomes into the clinic for the treatment of stroke and likely other forms of neurological injury and degenerative diseases.

Acknowledgments

This work was supported by the National Institute of Neurological Disorders and Stroke R01NS083078 (Dr Chen), R01NS099030 (Dr Chen), R01NS097747 (Dr Chen and Dr Jiang), and R01NS088656 (Dr Chopp).

Disclosures

None.

References

1. Ailawadi S, Wang X, Gu H, Fan GC. Pathologic function and therapeutic potential of exosomes in cardiovascular disease. *Biochim Biophys Acta*. 2015;1852:1–11. doi: 10.1016/j.bbadis.2014.10.008.
2. Belting M, Christianson HC. Role of exosomes and microvesicles in hypoxia-associated tumour development and cardiovascular disease. *J Intern Med*. 2015;278:251–263. doi: 10.1111/joim.12393.
3. Colombo E, Borgiani B, Verderio C, Furlan R. Microvesicles: novel biomarkers for neurological disorders. *Front Physiol*. 2012;3:63. doi: 10.3389/fphys.2012.00063.
4. Musante L, Tataruch DE, Holthofer H. Use and isolation of urinary exosomes as biomarkers for diabetic nephropathy. *Front Endocrinol (Lausanne)*. 2014;5:149. doi: 10.3389/fendo.2014.00149.
5. Javeed N, Mukhopadhyay D. Exosomes and their role in the micro-/macro-environment: a comprehensive review. *J Biomed Res*. 2017;31:386–394.
6. Chopp M, Zhang ZG. Emerging potential of exosomes and noncoding microRNAs for the treatment of neurological injury/diseases. *Expert Opin Emerg Drugs*. 2015;20:523–526. doi: 10.1517/14728214.2015.1061993.
7. Suzuki E, Fujita D, Takahashi M, Oba S, Nishimatsu H. Stem cell-derived exosomes as a therapeutic tool for cardiovascular disease. *World J Stem Cells*. 2016;8:297–305. doi: 10.4252/wjsc.v8.i9.297.
8. Zhang ZG, Chopp M. Exosomes in stroke pathogenesis and therapy. *J Clin Invest*. 2016;126:1190–1197. doi: 10.1172/JCI81133.
9. Luarte A, Bátiz LF, Wyneken U, Lafourcade C. Potential therapies by stem cell-derived exosomes in CNS diseases: focusing on the neurogenic niche. *Stem Cells Int*. 2016;2016:5736059. doi: 10.1155/2016/5736059.
10. Xin H, Li Y, Cui Y, Yang JJ, Zhang ZG, Chopp M. Systemic administration of exosomes released from mesenchymal stromal cells

promote functional recovery and neurovascular plasticity after stroke in rats. *J Cereb Blood Flow Metab*. 2013;33:1711–1715. doi: 10.1038/jcbfm.2013.152.
11. Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. *Annu Rev Physiol*. 2015;77:13–27. doi: 10.1146/annurev-physiol-021014-071641.
12. Lopez-Verrilli MA, Court FA. Exosomes: mediators of communication in eukaryotes. *Biol Res*. 2013;46:5–11. doi: 10.4067/S0716-97602013000100001.
13. Simons M, Raposo G. Exosomes–vesicular carriers for intercellular communication. *Curr Opin Cell Biol*. 2009;21:575–581. doi: 10.1016/j.ceb.2009.03.007.
14. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. *Front Cell Neurosci*. 2014;8:377. doi: 10.3389/fncel.2014.00377.
15. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr Protoc Cell Biol*. 2006;Chapter 3:Unit 3.22. doi: 10.1002/0471143030.cb0322s30.
16. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007;9:654–659. doi: 10.1038/ncb1596.
17. Choi DS, Kim DK, Kim YK, Gho YS. Proteomics of extracellular vesicles: exosomes and ectosomes. *Mass Spectrom Rev*. 2015;34:474–490. doi: 10.1002/mas.21420.
18. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol*. 2009;9:581–593. doi: 10.1038/nri2567.
19. Lakkaraju A, Rodriguez-Boulan E. Itinerant exosomes: emerging roles in cell and tissue polarity. *Trends Cell Biol*. 2008;18:199–209. doi: 10.1016/j.tcb.2008.03.002.
20. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat Rev Drug Discov*. 2013;12:847–865. doi: 10.1038/nrd4140.
21. Xu R, Greening DW, Zhu HJ, Takahashi N, Simpson RJ. Extracellular vesicle isolation and characterization: toward clinical application. *J Clin Invest*. 2016;126:1152–1162. doi: 10.1172/JCI81129.
22. Greening DW, Xu R, Ji H, Tauro BJ, Simpson RJ. A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods. *Methods Mol Biol*. 2015;1295:179–209. doi: 10.1007/978-1-4939-2550-6_15.
23. Lasser C, Eldh M, Lotvall J. Isolation and characterization of RNA-containing exosomes. *J Vis Exp*. 2012;59:e3037. doi: 10.3791/3037.
24. Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, et al. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. *Methods*. 2012;56:293–304. doi: 10.1016/j.ymeth.2012.01.002.
25. Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. *Proteomics*. 2013;13:3354–3364. doi: 10.1002/pmic.201300282.
26. Xu R, Simpson RJ, Greening DW. A protocol for isolation and proteomic characterization of distinct extracellular vesicle subtypes by sequential centrifugal ultrafiltration. *Methods Mol Biol*. 2017;1545:91–116. doi: 10.1007/978-1-4939-6728-5_7.
27. Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, Osobamiro O, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. *Cancer Lett*. 2013;335:201–204. doi: 10.1016/j.canlet.2013.02.019.
28. Ibsen SD, Wright J, Lewis JM, Kim S, Ko SY, Ong J, et al. Rapid isolation and detection of exosomes and associated biomarkers from plasma. *ACS Nano*. 2017;11:6641–6651. doi: 10.1021/acsnano.7b00549.
29. Welton JL, Webber JP, Botos LA, Jones M, Clayton A. Ready-made chromatography columns for extracellular vesicle isolation from plasma. *J Extracell Vesicles*. 2015;4:27269.
30. Tang YT, Huang YY, Zheng L, Qin SH, Xu XP, An TX, et al. Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum. *Int J Mol Med*. 2017;40:834–844. doi: 10.3892/ijmm.2017.3080.
31. Jeppesen DK, Hvam ML, Primdahl-Bengtson B, Boysen AT, Whitehead B, Dyrskjøt L, et al. Comparative analysis of discrete exosome fractions obtained by differential centrifugation. *J Extracell Vesicles*. 2014;3:25011.
32. Baranyai T, Herczeg K, Onódi Z, Voszka I, Módos K, Marton N, et al. Isolation of exosomes from blood plasma: qualitative and quantitative comparison of ultracentrifugation and size exclusion chromatography Methods. *PLoS One*. 2015;10:e0145686. doi: 10.1371/journal.pone.0145686.
33. Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, et al. The impact of disparate isolation methods for extracellular vesicles on downstream rna profiling. *J Extracell Vesicles*. 2014;3:24858. doi: 10.3402/jev.v3.24858.
34. Taylor DD, Zacharias W, Gercel-Taylor C. Exosome isolation for proteomic analyses and RNA profiling. *Methods Mol Biol*. 2011;728:235–246. doi: 10.1007/978-1-61779-068-3_15.
35. Lee M, Ban J-J, Im W, Kim M. Influence of storage condition on exosome recovery. *Biotechnol Bioprocess Eng*. 2016;21:299–304.
36. Tian T, Zhu YL, Zhou YY, Liang GF, Wang YY, Hu FH, et al. Exosome uptake through clathrin-mediated endocytosis and macropinocytosis and mediating miR-21 delivery. *J Biol Chem*. 2014;289:22258–22267. doi: 10.1074/jbc.M114.588046.
37. Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ, Chang LF, et al. Cellular internalization of exosomes occurs through phagocytosis. *Traffic*. 2010;11:675–687. doi: 10.1111/j.1600-0854.2010.01041.x.
38. Svensson KJ, Christianson HC, Wittrup A, Bourseau-Guilmain E, Lindqvist E, Svensson LM, et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. *J Biol Chem*. 2013;288:17713–17724. doi: 10.1074/jbc.M112.445403.
39. Fitzner D, Schnaars M, van Rossum D, Krishnamoorthy G, Dibaj P, Bakhti M, et al. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. *J Cell Sci*. 2011;124(pt 3):447–458. doi: 10.1242/jcs.074088.
40. Tian T, Zhu YL, Hu FH, Wang YY, Huang NP, Xiao ZD. Dynamics of exosome internalization and trafficking. *J Cell Physiol*. 2013;228:1487–1495. doi: 10.1002/jcp.24304.
41. Rana S, Zöller M. Exosome target cell selection and the importance of exosomal tetraspanins: a hypothesis. *Biochem Soc Trans*. 2011;39:559–562. doi: 10.1042/BST0390559.
42. Rana S, Yue S, Stadel D, Zöller M. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. *Int J Biochem Cell Biol*. 2012;44:1574–1584. doi: 10.1016/j.biocel.2012.06.018.
43. Haqqani AS, Delaney CE, Tremblay TL, Sodja C, Sandhu JK, Stanimirovic DB. Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells. *Fluids Barriers CNS*. 2013;10:4. doi: 10.1186/2045-8118-10-4.
44. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. *J Cell Biol*. 2013;200:373–383. doi: 10.1083/jcb.201211138.
45. Katakowski M, Chopp M. Exosomes as tools to suppress primary brain tumor. *Cell Mol Neurobiol*. 2016;36:343–352. doi: 10.1007/s10571-015-0280-9.
46. Pitt JM, André F, Amigorena S, Soria JC, Eggermont A, Kroemer G, et al. Dendritic cell-derived exosomes for cancer therapy. *J Clin Invest*. 2016;126:1224–1232. doi: 10.1172/JCI81137.
47. Selmaj I, Mycko MP, Raine CS, Selmaj KW. The role of exosomes in CNS inflammation and their involvement in multiple sclerosis. *J Neuroimmunol*. 2017;306:1–10. doi: 10.1016/j.jneuroim.2017.02.002.
48. de Rivero Vaccari JP, Brand F III, Adamczak S, Lee SW, Perez-Barcena J, Wang MY, et al. Exosome-mediated inflammasome signaling after central nervous system injury. *J Neurochem*. 2016;136(suppl 1):39–48. doi: 10.1111/jnc.13036.
49. Gupta A, Pulliam L. Exosomes as mediators of neuroinflammation. *J Neuroinflammation*. 2014;11:68. doi: 10.1186/1742-2094-11-68.
50. Chen J, Cui C, Yang X, Xu J, Venkat P, Zacharek A, et al. MiR-126 affects brain-heart interaction after cerebral ischemic stroke. *Transl Stroke Res*. 2017;8:374–385. doi: 10.1007/s12975-017-0520-z.
51. Bianco F, Pravettoni E, Colombo A, Schenk U, Möller T, Matteoli M, et al. Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. *J Immunol*. 2005;174:7268–7277.
52. Bianco F, Perrotta C, Novellino L, Francolini M, Riganti L, Menna E, et al. Acid sphingomyelinase activity triggers microparticle release from glial cells. *EMBO J*. 2009;28:1043–1054. doi: 10.1038/emboj.2009.45.
53. Balusu S, Van Wonterghem E, De Rycke R, Raemdonck K, Stremersch S, Gevaert K, et al. Identification of a novel mechanism of blood-brain communication during peripheral inflammation via choroid plexus-derived extracellular vesicles. *EMBO Mol Med*. 2016;8:1162–1183. doi: 10.15252/emmm.201606271.

54. Turola E, Furlan R, Bianco F, Matteoli M, Verderio C. Microglial microvesicle secretion and intercellular signaling. *Front Physiol*. 2012;3:149. doi: 10.3389/fphys.2012.00149.
55. Pusic KM, Pusic AD, Kraig RP. Environmental enrichment stimulates immune cell secretion of exosomes that promote CNS myelination and may regulate inflammation. *Cell Mol Neurobiol*. 2016;36:313–325. doi: 10.1007/s10571-015-0269-4.
56. EL Andaloussi S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. *Nat Rev Drug Discov*. 2013;12:347–357. doi: 10.1038/nrd3978.
57. Huang M, Hu YY, Dong XQ. High concentrations of procoagulant microparticles in the cerebrospinal fluid and peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome. *Surg Neurol*. 2009;72:481–489; discussion 489. doi: 10.1016/j.surneu.2008.12.016.
58. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. *Thromb Haemost*. 2007;97:425–434.
59. Horn P, Erkilet G, Veulemans V, Kröpil P, Schurgers L, Zeus T, et al. Microparticle-induced coagulation relates to coronary artery atherosclerosis in severe aortic valve stenosis. *PLoS One*. 2016;11:e0151499. doi: 10.1371/journal.pone.0151499.
60. Muhsin-Sharafaldine MR, Saunderson SC, Dunn AC, Faed JM, Kleffmann T, McLellan AD. Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. *Oncotarget*. 2016;7:56279–56294. doi: 10.18632/oncotarget.10783.
61. Porro C, Trotta T, Panaro MA. Microvesicles in the brain: biomarker, messenger or mediator? *J Neuroimmunol*. 2015;288:70–78. doi: 10.1016/j.jneuroim.2015.09.006.
62. Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles: targets and tools in cardiovascular disease. *Trends Pharmacol Sci*. 2011;32:659–665. doi: 10.1016/j.tips.2011.06.005.
63. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. *Stroke*. 2001;32:1005–1011.
64. Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. *Stroke*. 2001;32:2682–2688.
65. Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. *Stroke*. 2016;47:1817–1824. doi: 10.1161/STROKEAHA.116.012995.
66. Chen J, Venkat P, Zacharek A, Chopp M. Neurorestorative therapy for stroke. *Front Hum Neurosci*. 2014;8:382. doi: 10.3389/fnhum.2014.00382.
67. Otero-Ortega L, Gomez de Frutos MC, Laso-Garcia F, Rodriguez-Frutos B, Medina-Gutierrez E, Lopez JA, et al. Exosomes promote restoration after an experimental animal model of intracerebral hemorrhage [published online ahead of print January 1, 2017]. J Cereb Blood Flow Metab. doi: 10.1177/0271678X17708917. http://journals.sagepub.com/doi/10.1177/0271678X17708917.
68. Chen CC, Liu L, Ma F, Wong CW, Guo XE, Chacko JV, et al. Elucidation of exosome migration across the blood-brain barrier model in vitro. *Cell Mol Bioeng*. 2016;9:509–529. doi: 10.1007/s12195-016-0458-3.
69. Beer L, Mildner M, Gyöngyösi M, Ankersmit HJ. Peripheral blood mononuclear cell secretome for tissue repair. *Apoptosis*. 2016;21:1336–1353. doi: 10.1007/s10495-016-1292-8.
70. Yeo RW, Lai RC, Zhang B, Tan SS, Yin Y, Teh BJ, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. *Adv Drug Deliv Rev*. 2013;65:336–341. doi: 10.1016/j.addr.2012.07.001.
71. Xu JF, Yang GH, Pan XH, Zhang SJ, Zhao C, Qiu BS, et al. Altered microRNA expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. *PLoS One*. 2014;9:e114627. doi: 10.1371/journal.pone.0114627.
72. Xin H, Li Y, Liu Z, Wang X, Shang X, Cui Y, et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. *Stem Cells*. 2013;31:2737–2746. doi: 10.1002/stem.1409.
73. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Pérez Lanzón M, Zini N, et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. *Stem Cell Res Ther*. 2015;6:127. doi: 10.1186/s13287-015-0116-z.
74. Bian S, Zhang L, Duan L, Wang X, Min Y, Yu H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. *J Mol Med (Berl)*. 2014;92:387–397. doi: 10.1007/s00109-013-1110-5.
75. Zhang Y, Chopp M, Liu XS, Katakowski M, Wang X, Tian X, et al. Exosomes derived from mesenchymal stromal cells promote axonal growth of cortical neurons. *Mol Neurobiol*. 2017;54:2659–2673. doi: 10.1007/s12035-016-9851-0.
76. Xin H, Li Y, Buller B, Katakowski M, Zhang Y, Wang X, et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. *Stem Cells*. 2012;30:1556–1564. doi: 10.1002/stem.1129.
77. Xiong Y, Mahmood A, Chopp M. Emerging potential of exosomes for treatment of traumatic brain injury. *Neural Regen Res*. 2017;12:19–22. doi: 10.4103/1673-5374.198966.
78. Xiong Y, Zhang Y, Mahmood A, Chopp M. Investigational agents for treatment of traumatic brain injury. *Expert Opin Investig Drugs*. 2015;24:743–760. doi: 10.1517/13543784.2015.1021919.
79. Doeppner TR, Herz J, Görgens A, Schlechter J, Ludwig AK, Radtke S, et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. *Stem Cells Transl Med*. 2015;4:1131–1143. doi: 10.5966/sctm.2015-0078.
80. Ophelders DR, Wolfs TG, Jellema RK, Zwanenburg A, Andriessen P, Delhaas T, et al. Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia. *Stem Cells Transl Med*. 2016;5:754–763. doi: 10.5966/sctm.2015-0197.
81. Kim DK, Nishida H, An SY, Shetty AK, Bartosh TJ, Prockop DJ. Chromatographically isolated CD63+CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. *Proc Natl Acad Sci USA*. 2016;113:170–175.
82. Zhang Y, Chopp M, Meng Y, Katakowski M, Xin H, Mahmood A, et al. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. *J Neurosurg*. 2015;122:856–867. doi: 10.3171/2014.11.JNS14770.
83. Drommelschmidt K, Serdar M, Bendix I, Herz J, Bertling F, Prager S, et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate inflammation-induced preterm brain injury. *Brain Behav Immun*. 2017;60:220–232. doi: 10.1016/j.bbi.2016.11.011.
84. Chen KH, Chen CH, Wallace CG, Yuen CM, Kao GS, Chen YL, et al. Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke. *Oncotarget*. 2016;7:74537–74556. doi: 10.18632/oncotarget.12902.
85. El Bassit G, Patel RS, Carter G, Shibu V, Patel AA, Song S, et al. MALAT1 in human adipose stem cells modulates survival and alternative splicing of PKCδII in HT22 cells. *Endocrinology*. 2017;158:183–195. doi: 10.1210/en.2016-1819.
86. Hayon Y, Dashevsky O, Shai E, Brill A, Varon D, Leker RR. Platelet microparticles induce angiogenesis and neurogenesis after cerebral ischemia. *Curr Neurovasc Res*. 2012;9:185–192.
87. Hayon Y, Shai E, Varon D, Leker RR. The role of platelets and their microparticles in rehabilitation of ischemic brain tissue. *CNS Neurol Disord Drug Targets*. 2012;11:921–925.
88. Altmann P, Mildner M, Haider T, Traxler D, Beer L, Ristl R, et al. Secretomes of apoptotic mononuclear cells ameliorate neurological damage in rats with focal ischemia. *F1000Res*. 2014;3:131. doi: 10.12688/f1000research.4219.2.
89. Phinney DG, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix CM, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. *Nat Commun*. 2015;6:8472. doi: 10.1038/ncomms9472.
90. Ambros V. The functions of animal microRNAs. *Nature*. 2004;431:350–355. doi: 10.1038/nature02871.
91. Sen CK. MicroRNAs as new maestro conducting the expanding symphony orchestra of regenerative and reparative medicine. *Physiol Genomics*. 2011;43:517–520. doi: 10.1152/physiolgenomics.00037.2011.
92. Juranek JK, Geddis MS, Song F, Zhang J, Garcia J, Rosario R, et al. RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. *Diabetes*. 2013;62:931–943. doi: 10.2337/db12-0632.
93. O'Loughlin AJ, Woffindale CA, Wood MJ. Exosomes and the emerging field of exosome-based gene therapy. *Curr Gene Ther*. 2012;12:262–274.
94. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol*. 2011;29:341–345. doi: 10.1038/nbt.1807.
95. Kalani A, Chaturvedi P, Kamat PK, Maldonado C, Bauer P, Joshua IG, et al. Curcumin-loaded embryonic stem cell exosomes restored

neurovascular unit following ischemia-reperfusion injury. *Int J Biochem Cell Biol*. 2016;79:360–369. doi: 10.1016/j.biocel.2016.09.002.
96. Cui C, Ye X, Chopp M, Venkat P, Zacharek A, Yan T, et al. miR-145 regulates diabetes-bone marrow stromal cell-induced neurorestorative effects in diabetes stroke rats. *Stem Cells Transl Med*. 2016;5:1656–1667. doi: 10.5966/sctm.2015-0349.
97. Xin H, Katakowski M, Wang F, Qian JY, Liu XS, Ali MM, et al. MicroRNA cluster miR-17-92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats. *Stroke*. 2017;48:747–753. doi: 10.1161/STROKEAHA.116.015204.
98. Zhang Y, Ueno Y, Liu XS, Buller B, Wang X, Chopp M, et al. The microRNA-17-92 cluster enhances axonal outgrowth in embryonic cortical neurons. *J Neurosci*. 2013;33:6885–6894. doi: 10.1523/JNEUROSCI.5180-12.2013.
99. Xin H, Wang F, Li Y, Lu QE, Cheung WL, Zhang Y, et al. Secondary release of exosomes from astrocytes contributes to the increase in neural plasticity and improvement of functional recovery after stroke in rats treated with exosomes harvested from microRNA 133b-overexpressing multipotent mesenchymal stromal cells. *Cell Transplant*. 2017;26:243–257. doi: 10.3727/096368916X693031.
100. Carmichael ST. Emergent properties of neural repair: elemental biology to therapeutic concepts. *Ann Neurol*. 2016;79:895–906. doi: 10.1002/ana.24653.
101. Chen J, Zhang ZG, Li Y, Wang L, Xu YX, Gautam SC, et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. *Circ Res*. 2003;92:692–699. doi: 10.1161/01.RES.0000063425.51108.8D.
102. Jayaraman M, Radhakrishnan R, Mathews CA, Yan M, Husain S, Moxley KM, et al. Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer. *Genes Cancer*. 2017;8:566–576. doi: 10.18632/genesandcancer.144.
103. Latchana N, Abrams ZB, Howard JH, Regan K, Jacob N, Fadda P, et al. Plasma microRNA levels following resection of metastatic melanoma. *Bioinform Biol Insights*. 2017;11:1177932217694837. doi: 10.1177/1177932217694837.
104. Zhang H, Mao F, Shen T, Luo Q, Ding Z, Qian L, et al. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. *Oncol Lett*. 2017;13:669–676. doi: 10.3892/ol.2016.5462.
105. Chen P, Price C, Li Z, Li Y, Cao D, Wiley A, et al. Mir-9 is an essential oncogenic microrna specifically overexpressed in mixed lineage leukemia-rearranged leukemia. *Proc Natl Acad Sci USA*. 2013;110:11511–11516.
106. Fatima F, Nawaz M. Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy. *Chin J Cancer*. 2015;34:541–553. doi: 10.1186/s40880-015-0051-5.

KEY WORDS: exosomes ■ lipids ■ mesenchymal stromal cells ■ microRNAs ■ stroke

Exosome Therapy for Stroke

Jieli Chen and Michael Chopp

Stroke. 2018;49:1083-1090; originally published online April 18, 2018;
doi: 10.1161/STROKEAHA.117.018292
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Print ISSN: 0039-2499. Online ISSN: 1524-4628